glp-1 for bulimia receptor agonists: A novel pharmacotherapy binge eating (Binge eating disorder and nervosa)? A systematic review Bulimia nervosa

Bornebusch et al., 2019)

Hence, intrathecal exenatide administration shifted the gene expression profile of neuropathic rats closer to that of the sham group, demonstrating its capacity to normalize the transcriptional landscape [64]

But GIP receptors are also expressed on adipocytes, which gives these drugs additional metabolic effects. UAB at the forefront of GLP-1 research In December 2025, the FDA approved an oral version of GLP-1 semaglutide

U.BambergK.et al

However, it remains unclear whether vascular GLP-1 receptor expression changes under some conditions and which factors could affect vascular GLP-1 receptor expression